Research programme: Alzheimer's disease diagnostics and therapies - Lay Line Genomics

Drug Profile

Research programme: Alzheimer's disease diagnostics and therapies - Lay Line Genomics

Alternative Names: Anti-Aβ oligomers - LLG; Anti-beta-amyloid oligomers - LLG; Anti-proNerve Growth Factor - LLG; Anti-proNGF - LLG; Diagnostic antibody IM13 - LLG; NGF-based therapy - LLG

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Lay Line Genomics
  • Class
  • Mechanism of Action Amyloid beta-protein inhibitors; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Italy
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in Italy
  • 20 Jul 2006 Preclinical trials in Alzheimer's disease in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top